TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
May 5, 2025, 5:01 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Despite strong sales growth, the missed EPS target indicates underlying issues, affecting investor sentiment. Historically, similar misses have caused significant stock price drops.
AI summary
What happened, with direct paths to the underlying reporting
TGTX reported Q1 earnings per share of 3 cents, missing expectations. Sales reached $120.86 million, exceeding consensus of $118.43 million. Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption. Long-term projections for Briumvi revenue increased to $560 million for 2025. Stock fell 13.2% despite positive sales growth and future forecasts.
TGTX reported Q1 earnings per share of 3 cents, missing expectations.
Sales reached $120.86 million, exceeding consensus of $118.43 million.
Briumvi's U.S. net sales were $119.7 million, reflecting strong market adoption.
Long-term projections for Briumvi revenue increased to $560 million for 2025.
Stock fell 13.2% despite positive sales growth and future forecasts.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
TG Therapeutics reported positive Phase 1 results for subcutaneous BRIUMVI in myasthenia gravis, with 82% achieving MG-ADL MCID and an average gain over four points. The company p…
TG Therapeutics reported Phase 1 data on a high-concentration subcutaneous formulation showing >60% bioavailability relative to IV, with B-cell depletion comparable to IV and no n…
TGTX shares rose 6.60% post-revenue estimate announcement. Projected Q4 revenue for Briumvi is approximately $182 million. Total 2025 revenue is expected to reach $616 million. 20…
TGTX shares remain in an uptrend, signaling potential for continued gains. Recent breakout indicates bullish implications for TGTX stock. Resistance at $36.25 has been broken, enh…